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Over the past years cardiovascular magnetic reso-
nance (CMR) imaging has been increasingly used to
detect the presence of coronary artery disease and to
assess its functional consequences to the myocardium
[1]. Several approaches have been applied to detect
coronary artery disease with CMR including direct
visualization of coronary arteries and bypass grafts [2–
4] (magnetic resonance coronary angiography), the
characterization of myocardial tissue [5–8] (delayed
contrast enhancement) or the visualization of the
effects of induced ischemia [9–17] (wall motion
analysis or perfusion measurements). The latter is
particularly valuable in clinical decision making since
the detection of epicardial coronary luminal narrowing
alone does not necessarily predict its hemodynamic
consequences to the underlying myocardium.
In the last decades, pharmacological stress has been
extensively evaluated as an alternative stress method
and is particularly advised to those patients who are
not able to perform adequately either due to limited
exercise capability or a disabling disease. With the
development of rapid gradient systems and the routine
application of advanced CMR scanner systems, it has
become possible to perform cine imaging of the heart
at rest and under stress conditions with CMR. Since
space is limited within the MR scanner bore and
patient movement impairs image quality, pharmaco-
logical stress is preferred for CMR imaging. Research
efforts have been focused on the definition of the
clinical role of magnetic resonance pharmacological
stress for the detection of inducible wall motion
abnormalities, preferably using dobutamine stress
magnetic resonance (DSMR) [18–30]. High-dose
DSMR proved to be highly accurate for the detection
of inducible wall motion abnormalities and its
usefulness for determination of patient prognosis has
been shown [18–24]. DSMR at low-dose dobutamine
levels was found to be highly predictive of functional
improvement of resting wall motion abnormalities
after coronary revascularization procedures (detection
of viable myocardium) [25–27].
For induction of ischemic wall motion abnormal-
ities, adenosine/dipyridamole or dobutamine are
routinely used and the outcome is often considered
alike and interchangeable. In a landmark study by
Paetsch et al. [31], the results of a direct comparison
of dobutamine stress CMR, adenosine stress CMR
and adenosine stress CMR perfusion as assessed
during a single, combined examination with all stress
tests were evaluated against coronary angiography as
the standard of reference. This study proved that
dobutamine was superior to adenosine stress for the
detection of inducible wall motion abnormalities
related to the presence of epicardial coronary
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stenoses [ 50%, with DSMR and adenosine stress
CMR, yielding an overall diagnostic accuracy of 86
and 58%, respectively. Only for the detection of
coronary artery stenosis [ 75%, a reasonably good
diagnostic accuracy of adenosine stress CMR was
found. Based on this study, adenosine was not
considered suitable the detection of inducible wall
motion abnormalities resulting from epicardial coro-
nary stenoses. This finding is physiologically quite
understandable as adenosine is a vasodilatory agent
not necessarily inducing an ischemic response but
rather a maldistribution of flow [32, 33]. This
phenomenon explains the absence of wall motion
abnormalities in the absence of true myocardial
ischemia. As a result, adenosine in conjunction with
advanced CMR imaging might be better suited for
direct assessment of perfusion abnormalities rather
than detection of wall motion abnormalities.
Several studies have addressed the value of
adenosine in conjunction with CMR imaging in
terms of safety, diagnostic accuracy and prognosis
[34–39]. Recently, Greenwood et al. [40] determined
the safety and diagnostic accuracy of adenosine-stress
CMR perfusion imaging early after acute ST eleva-
tion myocardial infarction (STEMI) compared with
standard exercise tolerance testing in 35 patients
admitted with first acute STEMI. All patients under-
went a CMR imaging protocol which included rest
and adenosine-stress perfusion, viability, and cardiac
functional assessment. Adenosine stress CMR imag-
ing was well tolerated in all patients and no
complications occurred. CMR was more sensitive
and more accurate than exercise testing for detecting
significant coronary artery stenosis, and more sensi-
tive for predicting revascularization. It was concluded
that adenosine-stress CMR imaging is a safe proce-
dure early after acute STEMI and identifies patients
with significant coronary stenosis more accurately
than conventional exercise tolerance testing. Pilz
et al. [41] recently showed that a normal adenosine
stress CMR predicted a very low cardiac event rate
and an excellent 1-year prognosis in 128 patients with
suspected coronary artery disease. Adenosine-stress
CMR imaging may therefore serve as a reliable non-
invasive gatekeeper in reducing the number of
redundant coronary angiographies.
In the present issue of the International Journal of
Cardiovascular Imaging, Karamitsos et al. [42]
determined the safety and tolerance of adenosine
stress CMR first-pass perfusion imaging in 351
patients with suspected or known coronary artery
disease. In total, 233 patients (76%) were found to
have significant coronary artery disease of whom 128
patients (36%) had multi-vessel disease. There were
no deaths, myocardial infarctions, or episodes of
bronchospasm during the CMR study. Transient
second (Mobitz II) or third-degree atrioventricular
block occurred in 27 patients (8%). There were no
sustained episodes of advanced atrioventricular
block. Patients on beta-blocking agents or calcium-
channel antagonists were not at increased risk for
atrioventricular block. Transient chest pain was the
most common side effect in 199 subjects (57%). The
present study differs from previous studies by (1)
including a large percentage (86%) of patients with
angiographic data, (2) a prolonged infusion time
(4 min instead of 3 min routinely), and (3) more
importantly, the procedure was safe in patients with
multi-vessel disease. A limitation of the study was the
rather short follow-up time of 1 h after administration
of adenosine. However, given the very short half-time
(\10 s) of adenosine, major side effects beyond one
hour of administration are not to be expected.
Besides, aminophylline is a very useful and efficient
antidote to adenosine.
To summarize, it can be concluded that adenosine is
a very suitable agent for stress CMR perfusion
imaging, as it is well-tolerated and safe even in
patients with severe coronary artery disease. Conse-
quently, adenosine stress CMR imaging is a valuable
adjunctive modality in assessing myocardial perfusion
abnormalities with prognostic implications in patients
with suspected and known coronary artery disease.
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